A cute decompensated heart failure (ADHF) presents a major challenge for clinicians with an estimated 1 million admissions in the United States annually (1) . Despite major strides in chronic heart failure marked by significant mortality reductions of 33% to 35% with beta-blockers (2-4), 16% to 27% with angiotensin-converting enzyme inhibitors (5, 6) , 43% with hydralazine/isosorbide dinitrate (7) , and 24% to 30% with aldosterone antagonists (8, 9) , outcomes have changed little in ADHF.
In-hospital mortality rates have only modestly However, the evidence supporting such a decision is lacking, and the same concern has been conclusively demonstrated to be misplaced with regard to chronic heart failure management (2) (3) (4) . A small randomized clinical trial conducted in France showed continuation of beta-blockers did not significantly change inhospital mortality, 3-month rehospitalization, or 3-month mortality rates in ADHF (12). An observational study that assessed outcomes in the Italian Survey for Acute Heart Failure showed increased risk of in-hospital mortality associated with betablocker withdrawal (13) . Other observational studies showed either no change or reduced short-term mortality, rehospitalization, and combined mortality/rehospitalization rates when beta-blockers were discontinued in ADHF (14) (15) (16) (17) . To gain a better understanding of how beta-blocker discontinuation affects outcomes in ADHF, we conducted a systematic review and meta-analysis.
METHODS
The present review was conducted according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (18) .
SEARCH STRATEGY. Studies were identified by working with a biomedical librarian, and systematically searching the electronic databases EMBASE, PubMed, and COCHRANE from January 2000 through January 2015. We used the following key terms for all databases: acute decompensated heart failure, betablockers, mortality, hospitalization, survival analysis, heart failure, and outcomes. Only articles written in English and conducted in human studies were QUALITY OF STUDIES IN ANALYSIS. Assessment of bias was conducted as described by Downs and Black (19) with two independent reviewers assessing the studies (K.W.P. and J.M.N.). High, medium, and low risks of bias in reporting, external validity, internal validity-bias, internal validity-confounding, and power were quantified as previously described (20) .
STATISTICAL ANALYSIS. The natural logarithm of the study-specific RR estimates and their CIs from the observational studies were combined using a random-effects meta-analytic model (21) . As a sensitivity analysis, the RCT was included in a separate analysis. 
Prins et al. Table 1 . Of studies that were amenable to metaanalysis, there were 2,155 patients that continued beta-blocker therapy and 399 patients that discontinued beta-blocker therapy.
We conducted a bias analysis of all the identified studies and found low risk of reporting bias in all studies; medium risk of external validity bias in Heart rate and systolic blood pressures were extracted from these studies to assess for possible differences in disease severity in the retrospective studies and for indications to discontinue beta-blocker therapy. There were no significant differences in systolic blood pressure and heart rate when comparing the groups that either continued or discontinued betablocker therapy in any of the studies (Online Table 2 ).
The Bohm et al. (14) study did not report specific numbers for heart rate or systolic blood pressure, but did report there were no differences in rates of hypotension or bradycardia between the 2 groups.
IN-HOSPITAL MORTALITY. Two of the studies reported in-hospital mortality, which combined consisted of 431 patients that continued beta-blocker therapy and 219 patients that stopped beta-blocker therapy. Discontinuation of beta-blockers was associated with significantly increased risk of in-hospital mortality (RR: 3.72; 95% CI: 1.51 to 9.14) (Figure 3 ).
There was no heterogeneity observed between these 2 studies (I 2 ¼ 0%).
SHORT-TERM MORTALITY. Four studies, including the RCT, reported short-term mortality with follow-up ranging from 60 to 180 days. Across the 3 observational studies, there were 1,724 patients that continued beta-blocker therapy and 180 patients that discontinued beta-blockers. Discontinuation of beta-blockers was associated with a significantly increased risk of death (RR: 1.78; 95% CI: 1.13 to 2.79) ( Figure 4A ). There was no significant variability Green indicates low risk of bias, yellow indicates medium risk of bias, and red indicates high risk of bias.
FIGURE 3 Forest Plot for In-Hospital Mortality
Data shown are RR (95% CI). CI ¼ confidence interval; RR ¼ relative risk.
Prins et al.
J A C C : H E A R T F A I L U R E V O L . 3 , N O . 8 , 2 0 1 5
Beta-Blocker Withdrawal in Acute Decompensated Heart Failure A U G U S T 2 0 1 5 : 6 4 7 -5 3 between these 3 studies (I 2 ¼ 16.1%). There was no difference between this pooled estimate and the RCT estimate, and moreover, the combined estimate minimally changed with the addition of the RCT (RR: 1.61; 95% CI: 1.04 to 2.49) ( Figure 4B ).
SHORT-TERM REHOSPITALIZATION OR MORTALITY.
Four of the studies reviewed including the RCT reported a combined endpoint of short-term rehospitalization or mortality with follow-up ranging from 60 to 180 days. A total of 1,724 patients continued betablocker therapy and 180 patients discontinued betablocker therapy across the 3 observational studies.
Discontinuation of beta-blockers was associated with an increased risk of the combined endpoint of rehospitalization or mortality (RR: 1.84; 95% CI: 1.08 to 3.1) ( Figure 5A ). There was significant heterogeneity between these 3 studies (I 2 ¼ 68%). There was no difference between the combined effect in the observational studies and the RCT estimate, and there was no significant change in the pooled estimate when the RCT was included (RR: 1.59; 95% CI:
1.03 to 2.45) ( Figure 5B ). The IMPACT-HF study also reported that the rate of beta-blocker use at 60 days after discharge was 91% when initiated before discharge, in contrast to 73% when initiated post-discharge, highlighting the inertia that can follow decisions made in the inpatient setting (23). Taken together, these data suggest discontinuation of beta-blockers during hospitalization results in reduced beta-blocker usage at follow-up, which is likely to contribute to poorer long-term outcomes.
Another explanation for the beneficial effects of beta-blocker therapy in ADHF could have been that the patients that stopped beta-blockers were end-stage heart failure patients with poor hemodynamics. This seems less likely because there were no reported significant differences in systolic blood pressure in any of the studies (Online Table 2 ), and blood pressure was an adjusting variable in all of the retrospective studies (Online Table 1 ). Moreover, the Butler study showed discontinuation of betablockers was not associated with differences in invasive hemodynamics because right atrial pressure Although our study examined the effects of continuation versus stopping beta-blockers in ADHF, another strategy often used is reduction of betablocker dose. Although not specifically investigated in our study, we did come across 1 paper that showed that reduction of beta-blocker dose during ADHF was associated with increased 5-year mortality when compared with no dose change and survival was the same as those that discontinued beta-blockers (24) .
Future studies assessing beta-blocker dose changes in ADHF may be useful to further define how to handle beta-blockers in ADHF. Another limitation is that some of the studies had different timing in endpoints, which may have contributed to some variability in the meta-analysis.
However, studies that had longer duration of follow-up had higher risks of adverse event, which Analysis excluding the randomized controlled trial (A) and including the randomized controlled trial (B). Data shown are RR (95% CI). Abbreviations as in Figure 3 .
was consistent with a retrospective analysis of the COMET trial that showed that as time from hospitalization increased, the difference in outcomes between those that continued beta-blocker and those that discontinued beta-blockers became more apparent (24) .
CONCLUSIONS
Our meta-analysis showed that continuation of beta-blockers in ADHF was associated with significant reductions in risk of in-hospital mortality, short-term mortality, and short-term combined rehospitalization or death. These data suggest that beta-blockers should be continued in ADHF if the clinical situation allows in an attempt to reduce adverse outcomes. ACKNOWLEDGMENT The authors thank Amy Claussen for assistance with the literature search. 
